Kindai University Hospital

Osakasayama-shi 589-8511

4 studies enrolling now · 21 studies all time

What they study most

Acute Myeloid Leukemia, Advanced Solid Tumor, Atrial Fibrillation, B-cell Lymphoma, BRCA Mutated, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cervical Cancer, Cholangiocarcinoma

Studies at this site

• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer — Recruiting now
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors — Recruiting now
• JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC — Recruiting now
• Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Recruiting now
• Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) — Recruiting now
• Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) — Running, not enrolling
• Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Running, not enrolling
• Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy — Running, not enrolling
• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) — Running, not enrolling
• A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Running, not enrolling
• A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Running, not enrolling
• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis — Running, not enrolling
• Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) — Running, not enrolling
• Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL — Completed
• A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. — Running, not enrolling
• The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC — Completed
• Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia — Completed
• Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC — Stopped early
• Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA — Stopped early